idexx laboratories inc. - IDXX

IDXX

Close Chg Chg %
643.59 1.02 0.16%

Closed Market

644.61

+1.02 (0.16%)

Volume: 562.64K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: idexx laboratories inc. - IDXX

IDXX Key Data

Open

$642.39

Day Range

639.56 - 650.38

52 Week Range

356.25 - 769.98

Market Cap

$51.34B

Shares Outstanding

79.85M

Public Float

78.97M

Beta

1.67

Rev. Per Employee

N/A

P/E Ratio

49.20

EPS

$13.18

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

526.56K

 

IDXX Performance

1 Week
 
-3.86%
 
1 Month
 
-9.64%
 
3 Months
 
-9.01%
 
1 Year
 
40.20%
 
5 Years
 
28.24%
 

IDXX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About idexx laboratories inc. - IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDXX At a Glance

IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092-2040
Phone 1-207-556-0300 Revenue 4.30B
Industry Medical Specialties Net Income 1.06B
Sector Health Technology 2025 Sales Growth 10.422%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

IDXX Valuation

P/E Current 49.204
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 51.722
Price to Sales Ratio 12.737
Price to Book Ratio N/A
Price to Cash Flow Ratio 46.38
Enterprise Value to EBITDA N/A
Enterprise Value to Sales 12.892
Total Debt to Enterprise Value 0.015

IDXX Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 7.791
Total Asset Turnover 1.295

IDXX Liquidity

Current Ratio 1.231
Quick Ratio 0.902
Cash Ratio 0.157

IDXX Profitability

Gross Margin 61.797
Operating Margin 31.601
Pretax Margin 30.769
Net Margin 24.618
Return on Assets 31.891
Return on Equity 66.202
Return on Total Capital 43.187
Return on Invested Capital 51.391

IDXX Capital Structure

Total Debt to Total Equity 52.812
Total Debt to Total Capital 34.56
Total Debt to Total Assets 25.303
Long-Term Debt to Equity 23.349
Long-Term Debt to Total Capital 15.28
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Idexx Laboratories Inc. - IDXX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.37B 3.66B 3.90B 4.30B
Sales Growth
+4.73% +8.72% +6.46% +10.42%
Cost of Goods Sold (COGS) incl D&A
1.39B 1.47B 1.52B 1.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 111.90M 114.91M 129.94M
Depreciation
- 96.90M 101.11M 112.84M
Amortization of Intangibles
- 15.00M 13.80M 17.10M
COGS Growth
+5.71% +6.18% +3.39% +7.85%
Gross Income
1.98B 2.19B 2.37B 2.66B
Gross Income Growth
+4.05% +10.51% +8.53% +12.08%
Gross Profit Margin
+58.76% +59.72% +60.88% +61.80%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.10B 1.09B 1.25B 1.30B
Research & Development
254.82M 190.95M 219.79M 251.21M
Other SG&A
849.55M 902.99M 1.03B 1.05B
SGA Growth
+15.67% -0.94% +13.89% +4.31%
Other Operating Expense
- - - (2.20M)
-
Unusual Expense
- - (2.80M) (1.60M)
-
EBIT after Unusual Expense
879.23M 1.09B 1.13B 1.36B
Non Operating Income/Expense
- 23.40M 10.24M 17.18M
Non-Operating Interest Income
- 1.06M 5.63M 12.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
42.66M 41.58M 36.07M 35.84M
Interest Expense Growth
+30.82% -2.52% -13.25% -0.64%
Gross Interest Expense
42.66M 41.58M 36.07M 35.84M
Interest Capitalized
- - - -
-
Pretax Income
859.97M 1.06B 1.11B 1.32B
Pretax Income Growth
-4.73% +23.40% +4.59% +19.31%
Pretax Margin
+25.54% +28.99% +28.48% +30.77%
Income Tax
180.88M 216.13M 221.96M 264.73M
Income Tax - Current - Domestic
- 180.63M 231.64M 205.15M
Income Tax - Current - Foreign
- 35.14M 32.80M 41.00M
Income Tax - Deferred - Domestic
- (37.40M) (42.96M) (29.35M)
Income Tax - Deferred - Foreign
- 2.52M (5.34M) 5.16M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
679.09M 845.04M 887.87M 1.06B
Minority Interest Expense
- - - -
-
Net Income
679.09M 845.04M 887.87M 1.06B
Net Income Growth
-8.83% +24.44% +5.07% +19.33%
Net Margin Growth
+20.17% +23.08% +22.78% +24.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
679.09M 845.04M 887.87M 1.06B
Preferred Dividends
- - - -
-
Net Income Available to Common
679.09M 845.04M 887.87M 1.06B
EPS (Basic)
8.1208 10.1731 10.7663 13.173
EPS (Basic) Growth
-7.11% +25.27% +5.83% +22.35%
Basic Shares Outstanding
83.62M 83.07M 82.47M 80.43M
EPS (Diluted)
8.0271 10.0627 10.6656 13.08
EPS (Diluted) Growth
-6.70% +25.36% +5.99% +22.64%
Diluted Shares Outstanding
84.60M 83.98M 83.25M 81.03M
EBITDA
- 988.33M 1.21B 1.26B
EBITDA Growth
- -6.14% +22.17% +4.11%
EBITDA Margin
- +29.35% +32.98% +32.25%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 784.154
Number of Ratings 18 Current Quarters Estimate 3.434
FY Report Date 03 / 2026 Current Year's Estimate 14.523
Last Quarter’s Earnings 3.08 Median PE on CY Estimate N/A
Year Ago Earnings 13.08 Next Fiscal Year Estimate 16.427
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 10 12 12
Mean Estimate 3.43 3.94 14.52 16.43
High Estimates 3.60 4.03 14.73 16.89
Low Estimate 3.37 3.80 14.34 16.02
Coefficient of Variance 1.75 1.65 0.79 1.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 3 3 2
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Idexx Laboratories Inc. - IDXX

Date Name Shares Transaction Value
Aug 13, 2025 Jonathan J. Mazelsky President and CEO; Director 83,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $598.49 per share 49,970,324.06
Aug 13, 2025 Jonathan J. Mazelsky President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 11,606 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $206.94 per share 2,401,745.64
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 6,156 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $651.6 per share 4,011,249.60
Aug 13, 2025 Sharon E. Underberg EVP, GC & Corporate Secretary 6,339 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $544.08 per share 3,448,923.12
Feb 20, 2025 George J. Fennell Executive Vice President 112 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 303 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,820 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,512 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Brian Patrick McKeon EVP, CFO and Treasurer 31,209 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 417 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 816 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 3,415 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 8,347 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $444.53 per share 3,710,491.91
Feb 20, 2025 Michael P. Johnson Executive Vice President 535 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 George J. Fennell Executive Vice President 8,340 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Idexx Laboratories Inc. in the News